Acne scars Acne scar, picosecond laser, 1064 nm laser, pulse duration
Conditions
Interventions
Participants will receive treatment with an 8 mm spot size, 450 ps pulse duration, 0.4-1.0 J per cm2 fluence for 4 passes.,Participants will receive treatment with an 8 mm spot size, 450 ps, 0.4-1.0 J
Experimental Device,Experimental Device
Short pulse duration picosecond laser,Combined pulse duration picosecond laser
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male and female volunteers aged 20-60 years. 2. Participants with moderate or greater atrophic acne scars on both sides of the face, with comparable severity, as assessed by the Qualitative Global Scarring Grading System. 3. Participants who voluntarily consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Participants who are pregnant or breastfeeding 2. Participants with a history of connective tissue disorders such as Cushing syndrome or Ehlers Danlos syndrome 3. Participants with dermatitis wounds or skin infections on the face 4. Participants with cancer currently undergoing cancer treatment or with skin cancer in the treatment area 5. Participants with a history of immunodeficiency including HIV infection or AIDS 6. Participants with a history of abnormal photosensitivity 7. Participants who have received facial treatments with dermal fillers botulinum toxin collagen biostimulators platelet rich plasma or thread lifting within 6 months prior to study enrollment 8. Participants who have received laser treatment for acne scars on the face within 6 months prior to study enrollment 9. Participants with a history of keloids or skin lesions in the treatment area 10. Participants who have received vitamin A or its derivatives within 6 months prior to study enrollment 11. Participants with a history of psychiatric disorders as evaluated by a qualified physician 12. Participants with any condition that in the investigators opinion may pose a safety risk if participating in the study 13. Participants who do not consent to photography for treatment evaluation 14. Participants with bleeding disorders or currently taking anticoagulants antiplatelet drugs or NSAIDs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| texture Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 1 month after 4th treatment, 3 months after 4th treatment, 6 months months after 4th treatment Antera,Depression volume Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 1 month after 4th treatment, 3 months after 4th treatment, 6 months months after 4th treatment Antera,Acne scar improvement Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 1 month after 4th treatment, 3 months after 4th treatment, 6 months months after 4th treatment Goodman and Baron's Quantitative Global Acne Scarring Grading System | — |
Secondary
| Measure | Time frame |
|---|---|
| Melanin Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 1 month after 4th treatment, 3 months after 4th treatment, 6 months months after 4th treatment Mexameter and visia,Erythema Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 1 month after 4th treatment, 3 months after 4th treatment, 6 months months after 4th treatment Mexameter and visia,Physician improvement scale 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 1 month after 4th treatment, 3 months after 4th treatment, 6 months months after 4th treatment Quartile scale,Patient improvement scale 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 1 month after 4th treatment, 3 months after 4th treatment, 6 months months after 4th treatment Quartile scale,Safety 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 1 month after 4th treatment, 3 months after 4th treatment, 6 months months after 4th treatment Adverse event | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed